Contents

Page Numbers	Session	Program numbers
3	TC1 - Current Controversy in Management: Interactive Case Discussion	TC1
3	TC2 - How do I choose the correct disease-modifying treatment?	TC2.1 – TC2.3
4	TC3 - Symptom management	TC3.1 – TC3.3
4	TC4 - Management during pregnancy	TC4
5	TC5 - Clinically isolated syndromes (CIS)	TC5.1 – TC5.3
6	TC6 - Neuromyelitis optica (NMO)	TC6.1 – TC6.3
7	TC7 - Imaging small parts of the nervous system (MAGNIMS)	TC7.1 – TC7.3
7	TC8 - Update in pediatric MS	TC8.1 – TC8.3
8	TC9 - Differential diagnoses and diagnostic dilemmas	TC9.1 – TC9.3
9	TC10 - Neuroimmunology in relation to MS pathophysiology	TC10.1 – TC10.3 and immunotherapy
9	TC11 - MRI issues in clinical practice (MAGNIMS)	TC11.1 – TC11.3
10	TC12 - Neuro-ophthalmology update	TC12.1 – TC12.3
11	TC13 - Assessing the drug efficacy: Challenges in study design	TC13.1 – TC13.3
12	TC 14 - Neuropsychiatric manifestations and cognitive impairment	TC14.1 – TC14.3
14	YI1 - Young Investigators 1	YI1.1 – YI1.7
17	YI2 - Young Investigators 2	YI2.1 – YI2.6
20	PL1 - Approaching the cause of multiple sclerosis	PL1.1
20	PS1 - Cell-based therapies	PS1.1 – PS1.6
23	PS2 - MS subpopulations and disease variants	PS2.1 – PS2.6
25	PS3 - MRI	PS3.1 – PS3.6
27	PS4 - EAE and other animal models	PS4.1 – PS4.6
30	PS5 - Comorbidities and risk behaviors	PS5.1 – PS5.6
32	PS6 - Risk management with MS therapies	PS6.1 – PS6.6
34	HT1 - Genetics of MS	HT1.1 – HT1.3
35	HT2 - New routes of drug development	HT2.1 – HT2.3
37	HT3 - Symptomatic and rehabilitation strategies	HT3.1 – HT3.3
38	FC1 - Free Communication 1	FC1.1 – FC1.5
40	FC2 - Free Communication 2	FC2.1 – FC2.5
43	FC3 - Free Communication 3	FC3.1 – FC3.5
45	FC4 - Free Communication 4	FC4.1 – FC4.5
48	PS7 - Biomarkers	PS7.1 – PS7.6
50	PS8 - Assessing neuroprotection	PS8.1 – PS8.6
52	PS9 - Treatment strategies in clinical practice	PS9.3 – PS9.6
55	PS10 - Immune mechanisms	PS10.1 – PS10.6
58	PS11 - Gray matter pathology and mechanisms of progression	PS11.1 – PS11.6
60	PS12 - Study design and endpoints	PS12.1 – PS12.6
63	HT4 - Remyelination	HT4.1 – HT4.3
64	HT5 - Inflammation and neurodegeneration	HT5.1 – HT5.3
65	HT6 - Society and MS	HT6.1 – HT6.3
66	PL2 - Paty Closing Lecture: Neuroprosthetics for paralysis	PL2.1
Posters 1
67	Caregivers, employment, and healthcare utilization	P001 – P032
81	Clinical outcome measures	P033 – P038
83	Clinical trials	P039 – P113
118	Cognitive function	P114 – P173
145	Comorbidities and risk behaviors	P174 – P194
154	CSF studies	P195 – P215
163	Databases	P216 – P221
166	Diagnosis and differential diagnosis	P222 – P241
175	Disease biomarkers	P241 – P279
191	Disease therapy	P280 – P329
214	Epidemiology	P330 – P373
233	Experimental models	P374 – P410
249	Genetics and epigenetics	P411 – P429
257	Imaging-1	P430 – P490
Posters 2
285	Imaging-2	P491 – P556
314	Immunology	P557 – P605
334	Internet and social media	P606 – P610
336	Microbiome	P611 – P618
340	Neurobiology	P619 – P628
344	Neuromyelitis optica	P629 – P654
355	Neuro-ophthalmology and OCT	P655 – P678
365	Neuropathology	P679 – P694
372	Neurophysiology	P695 – P707
377	Neuroprotection and repair	P708 – P732
388	Neuropsychiatric aspects	P733 – P743
393	Pediatric MS	P744 – P757
399	Prognostic factors	P758 – P771
405	PROs and QOL	P772 – P806
421	Rehabilitation and comprehensive care	P807 – P837
434	Reproductive aspects and pregnancy	P838 – P856
443	Risk management for disease therapies	P857 – P888
456	Stem cells and cell-based therapy	P889 – P903
462	Symptom management	P904 – P948
481	Treatment biomarkers, pharmacology, and MOA	P949 – P981
Late Breaking News
497	Platform Presentation	LB1.1 – LB1.7
501	Poster Presentation	LBP1 – LBP22
Author Index